ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

milvexian

Also written as “BMS-986177”, “Milvexian” and “JNJ-70033093”.

Its studies are mostly in Thrombosis · Ischemic Stroke · Atrial Fibrillation · Acute Coronary Syndrome · Stroke, led by 2 companies.

Drug pageMilvexian: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 20, 201625 company-led studies, 2 open or runningCo-development: Bristol Myers Squibb and Janssen (Johnson & Johnson), Apr 2018Next primary completion: Dec 8, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only140 open or runningphase 2since Dec 20, 2016Nov 17, 2015none ahead
Johnson & Johnsonits history only112 open or runningphase 3since Jan 19, 2023Mar 25, 2019Dec 8, 2026phase 3 · NCT05757869
  • Named in Bristol-Myers Squibb’s own pipeline as milvexian, phase 3, as of Oct 29, 2026 (source).
  • Named in Johnson & Johnson’s own pipeline as milvexian, phase 3, as of Oct 13, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Nov 17, 2015.

  1. Apr 16, 2018Janssen (Johnson & Johnson) develops it with Bristol Myers SquibbCo-developmentWorldwide, development costs and profits shared · announced · Johnson & Johnson
  2. Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
  3. Nov 13, 2018Phase 2 study in Ischemic StrokeBristol-Myers Squibb · NCT03766581 · 2,366 enrolled · United States, Argentina, Australia and more
  4. Mar 25, 2019Johnson & Johnson’s first study: phase 2 study in Arthroplasty, Replacement, KneeNew to Johnson & JohnsonJohnson & Johnson · NCT03891524 · 1,242 enrolled · United States, Argentina, Belgium and more
  5. May 2, 2019Phase 1 study in ThrombosisBristol-Myers Squibb · NCT03939702 · 9 enrolled · United States
  6. Dec 18, 2019Phase 1 study in HealthyJohnson & Johnson · NCT04206488 · 30 enrolled · Belgium
  7. Jan 8, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04223349 · 66 enrolled · United States
  8. May 12, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04388501 · 23 enrolled · Belgium
  9. Jun 9, 2020Named milvexianINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986177, JNJ-70033093
  10. Jun 25, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04448964 · 24 enrolled · Belgium
  11. Sep 11, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04569695 · 40 enrolled · China
  12. Apr 12, 2021Phase 1 study in HealthyJohnson & Johnson · NCT04844424 · 115 enrolled · United States
  13. Jul 7, 2021Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04965389 · 17 enrolled · United Kingdom
  14. Jan 19, 2023Phase 3 study in Ischemic StrokeJohnson & Johnson · NCT05702034 · 12,523 enrolled · United States, Argentina, Australia and more
  15. Jan 23, 2023Phase 1 study in Healthy FemaleJohnson & Johnson · NCT05706753 · 20 enrolled · Belgium
  16. Feb 23, 20232 phase 3 studiesJohnson & Johnson · NCT05754957, NCT05757869

Ahead

  1. Dec 8, 2026Primary completion: phase 3 study in Atrial FibrillationJohnson & Johnson · NCT05757869

TargetBeta

“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation”study text, read by Claude · the study

Other programs on F11

ProgramCompanyFurthest phaseStudies
abelacimabanthos-therapeutics-incphase 38
SHR-2004Jiangsu HengRui Medicinephase 35

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05757869Atrial Fibrillation · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonDec 8, 202620,284
NCT05754957Acute Coronary Syndrome · United States, Argentina, Australia and more3CompletedJohnson & JohnsonFeb 6, 202614,194
NCT05706753Healthy Female · Belgium1CompletedJohnson & JohnsonJul 20, 202320
NCT05702034Ischemic Stroke · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonOct 15, 202612,523
NCT04965389Healthy Volunteers · United Kingdom1CompletedBristol-Myers SquibbAug 22, 202117
NCT04844424Healthy · United States1CompletedJohnson & JohnsonMay 6, 2022115
NCT04569695Healthy · China1CompletedJohnson & JohnsonDec 4, 202140
NCT04448964Healthy · Belgium1CompletedJohnson & JohnsonNov 14, 202024
NCT04388501Healthy · Belgium1CompletedJohnson & JohnsonOct 25, 202123
NCT04223349Healthy · United States1CompletedJohnson & JohnsonApr 8, 202066
NCT04206488Healthy · Belgium1CompletedJohnson & JohnsonJun 9, 202130
NCT03939702Thrombosis · United States1CompletedBristol-Myers SquibbJul 11, 20199
NCT03891524Arthroplasty, Replacement, Knee · United States, Argentina, Belgium and more2CompletedJohnson & JohnsonApr 6, 20211,242
NCT03766581Ischemic Stroke · United States, Argentina, Australia and more2CompletedBristol-Myers SquibbMar 31, 20222,366
NCT03698513Healthy Volunteers · United States1CompletedBristol-Myers SquibbFeb 19, 2019113
NCT03362437Thrombosis · United Kingdom1CompletedBristol-Myers SquibbDec 28, 201712
NCT03341390Stroke · United States1CompletedBristol-Myers SquibbNov 16, 201720
NCT03224260Thrombosis · United States1CompletedBristol-Myers SquibbNov 7, 201733
NCT03196206Thrombosis · United States1CompletedBristol-Myers SquibbMar 4, 201824
NCT03000673Antithrombotic · United States2CompletedBristol-Myers SquibbOct 23, 201732
NCT02982707Thrombosis · United States1CompletedBristol-Myers SquibbSep 28, 201826
NCT02959060Thrombosis1CompletedBristol-Myers SquibbDec 201616
NCT02902679Thrombosis · United States1CompletedBristol-Myers SquibbJun 20176
NCT02807909Thrombosis1CompletedBristol-Myers SquibbAug 201628
NCT02608970Thrombosis · Belgium1CompletedBristol-Myers SquibbJul 23, 2017104

How it is read

Names in the registry

  • “BMS-986177”, 14 entries
  • “Milvexian”, 6 entries
  • “JNJ-70033093”, 4 entries
  • “JNJ-70033093 25 mg”, 1 entry
  • “JNJ-70033093 50 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.